Drug database
JAMS 2.0
Joint Action on Reinforced Market Surveillance of Medical Devices and In Vitro Medical Devices
The Joint Action (JAMS 2.0) aims to reinforce the market surveillance of medical devices (MDs) and in vitro devices (IVDs) between Member States and harmonise approaches across the European Union. Parallel to the ongoing implementation of MD/IVD Regulations, the actions carried out lay the ground work to increased dialogue. This will facilitate future coordination between Competent Authorities (CAs) through the adoption of aligned and consistent work methods. By strengthening coordination, JAMS 2.0 helps to increase the safety of medical devices. Therefore, it will contribute effectively to public health protection, by ensuring that medical devices available on the market are safe, perform as intended and remain compliant with the regulations in place. JAMS 2.0 is Co-funded by the European Health and Digital Executive Agency (HaDEA) through the EU4Health programme, this Joint Action will also allow to share best practices and develop trainings on Market Surveillance of MDs/IVDs. The results of JAMS 2.0 are expected by the end of 2026.
The project is divided into 8 work packages
- Coordination,
- Dissemination,
- Assessment,
- Sustainability,
- Signal detection and vigilance,
- Inspection,
- Market surveillance campaign,
- MD/IVMD university)
